These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24641830)

  • 1. Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors.
    Pfeil AM; Vulsteke C; Paridaens R; Dieudonné AS; Pettengell R; Hatse S; Neven P; Lambrechts D; Szucs TD; Schwenkglenks M; Wildiers H
    BMC Cancer; 2014 Mar; 14():201. PubMed ID: 24641830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
    Vulsteke C; Lambrechts D; Dieudonné A; Hatse S; Brouwers B; van Brussel T; Neven P; Belmans A; Schöffski P; Paridaens R; Wildiers H
    Ann Oncol; 2013 Jun; 24(6):1513-25. PubMed ID: 23396606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
    Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
    Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.
    Sugishita M; Imai T; Kikumori T; Mitsuma A; Shimokata T; Shibata T; Morita S; Inada-Inoue M; Sawaki M; Hasegawa Y; Ando Y
    Breast Cancer; 2016 Mar; 23(2):195-201. PubMed ID: 25008867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of the Risk Factors of Febrile Neutropenia Among 72 Women Receiving FEC in Early Breast Cancer Chemotherapy].
    Ishii N; Fujimori T; Kasagawa T; Udagawa I
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1555-1557. PubMed ID: 28133055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.
    Charehbili A; de Groot S; van der Straaten T; Swen JJ; Pijl H; Gelderblom H; van de Velde CJ; Nortier JW; Guchelaar HJ; Kroep JR
    Pharmacogenomics; 2015; 16(11):1267-76. PubMed ID: 26289095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.
    Bacrie J; Laurans M; Iorio P; Fourme E; Volters AB; Bozec L; Lerebours F; Dubot C; Bensaoula O; Benzidane B; Pierga JY; Lefeuvre D
    Support Care Cancer; 2018 Dec; 26(12):4097-4103. PubMed ID: 29855772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.
    Netterberg I; Karlsson MO; Nielsen EI; Quartino AL; Lindman H; Friberg LE
    Br J Clin Pharmacol; 2018 Mar; 84(3):490-500. PubMed ID: 29178353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.
    Vulsteke C; Pfeil AM; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Peeters M; van Dam P; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
    Breast Cancer Res Treat; 2014 Oct; 147(3):557-70. PubMed ID: 25168315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.
    van Dooijeweert C; van der Wall E; Baas IO
    Neth J Med; 2019 Dec; 77(9):310-316. PubMed ID: 31814585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study.
    Ishikawa T; Sakamaki K; Narui K; Nishimura H; Sangai T; Tamaki K; Hasegawa Y; Watanabe KI; Suganuma N; Michishita S; Sugae S; Aihara T; Tsugawa K; Kaise H; Taira N; Mukai H;
    Breast; 2021 Apr; 56():70-77. PubMed ID: 33631458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
    Lee EK; Wong WW; Trudeau ME; Chan KK
    Breast Cancer Res Treat; 2015 Feb; 150(1):169-80. PubMed ID: 25694355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
    Vulsteke C; Pfeil AM; Maggen C; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
    Breast Cancer Res Treat; 2015 Jul; 152(1):67-76. PubMed ID: 26017071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: A retrospective cohort study on duration of prophylactic GCSF administration.
    Lee CF; Zhou K; Young WM; Wong CS; Ng TY; Lee SF; Leung K; Wong LKM; So KH; Tang W; Chong G; Chan SK; Yip YTE; Ma VYM; Yeung A; Chin CHY; Kwan MW; Tsang HT
    Support Care Cancer; 2020 Aug; 28(8):3801-3812. PubMed ID: 31832822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients.
    Faraji A; Dehghan Manshadi HR; Mobaraki M; Zare M; Houshmand M
    PLoS One; 2016; 11(12):e0168519. PubMed ID: 28036387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy.
    Suzuki K; Sasada S; Nishi H; Kimura Y; Shintani T; Emi A; Masumoto N; Kadoya T; Kawaguchi H; Okada M
    Breast Cancer; 2023 Jan; 30(1):151-155. PubMed ID: 36271187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
    Okishiro M; Kim SJ; Tsunashima R; Nakayama T; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Apr; 132(3):947-53. PubMed ID: 21706156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
    Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.